Marker Therapeutics, Inc. MRKR 深 滬
已收盤 07-18 16:00:00 美东时间
1.70
-0.220
-11.46%
華盛通- 最 高1.8899
- 今 開1.80
- 成交量 177.57万股
- 最 低 1.63
- 昨 收 1.92
- 總市值 1923.52万
- 52周最高 5.95
- 市盈率 靜 --
- 換手率 15.69%
- 52周最低 0.95
- 委 比 35.93%
- 總股本 1131.48万
- 歷史最高 99.00
- 量 比 0.14
- 振 幅 13.54%
- 歷史最低 0.95
- 每 手 1
- 風險率 1.20%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Marker Therapeutics Collaborates With Cellipont Bioservices To Accelerate cGMP Manufacturing Of MT-601 MAR-T Cell Therapy For Lymphoma
Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor
06-17 20:08
Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma
Marker Therapeutics collaborates with Cellipont Bioservices to manufacture MT-601, a Multi-Antigen Recognizing T cell therapy for lymphoma patients. MT-601 has shown promising results in the Phase 1 APOLLO study, with 78% of participants experiencing objective responses. The partnership aims to accelerate clinical supply and prepare for potential pivotal trials. Both companies emphasize their commitment to advancing innovative immunotherapies to ...
06-17 12:00
Marker Therapeutics Concludes Annual Stockholders Meeting
Marker Therapeutics ( ($MRKR) ) just unveiled an update. On June 6, 2025, Marke...
06-10 04:28
Marker Therapeutics To Highlight Multi-Antigen Recognizing-T Cells In High-Profile Panel On CAR-T Cell Therapies
MARKER THERAPEUTICS, INC. (NASDAQ:MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid
05-19 20:10
美股大行评级 | 潜在涨幅4159%！HC Wainwright & Co.上调BiomX目标价至21美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1114111385008877568.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持BiomX(PHGE)"买入"评级，目标价从2美元升至21美元</p> <p>• HC Wainwright & Co.：维持Unicycive Therapeu
04-02 09:42
美股机会日报丨美股期指大跌！华尔街模型预测衰退概率最高达50%
美股指数盘前重挫！标普500指数期货跌1.25%，英伟达跌超3%；华尔街模型预测衰退概率最高达50%；京东盘前涨超6%，拟回购最多50亿美元股票>>
03-06 21:11
美股大行评级 | 富国银行：维持艾伯维"超配"评级，目标价从210美元升至240美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1104327819967434752.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 摩根大通：维持Syndax制药(SNDX)"超配"评级，目标价从35美元升至39美元</p> <p>• 摩根大通：维持AnaptysBio(ANAB)"超配"评级，目标价从36美元升至42美元</p> <p>• 摩根大通
03-06 11:20
Marker Therapeutics Grants Stock Options to Directors
Marker Therapeutics ( ($MRKR) ) has provided an announcement. On February 12, 2...
02-20 06:29
快讯 | Marker Therapeutics Inc 向证券交易委员会提交文件，申请由出售股东转售高达 10.1 万股的股份。
Marker Therapeutics Inc Files for Resale of up to 10.1 Mln Shares by the Sellin...
01-11 06:10
Marker Therapeutics pops on receiving $9.5M grant to advance lead asset
Marker Therapeutics (NASDAQ:MRKR) shares popped 11% Tuesday morning after the immuno-oncology company won a $9.5M grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to support the ...
2024-12-17 21:33
